A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • Medicines Patent Pool: Transparency is essent...
Publication - published on 01 Sep 2020

Medicines Patent Pool: Transparency is essential to access to medicines

In this viewpoint for Medicines Patent Pool's "10 Years of MPP" campaign, Executive Director Jayasree K. Iyer discusses the need for transparency from pharmaceutical companies in order to improve access to medicine.

In this piece, Dr. Iyer explains the relationship between the Access to Medicine Foundation and Medicines Patent Pool (MPP), which has become the main driving force behind voluntary licensing in the pharmaceutical industry.

Whether medicines, vaccines and other products reach the people who need them, especially those in low- and middle-income countries, depends on the strategic choices companies make to support affordable access. This viewpoint stresses the need for pharma companies to be transparent about their activities in order to make their medicines more accessible and affordable.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |